ZEPBOUND Drug Patent Profile

When do Zepbound patents expire, and when can generic versions of Zepbound launch?

Zepbound is a drug marketed by Eli Lilly And Co and is included in one NDA. There are six patents protecting this drug.

This drug has two hundred and one patent family members in forty-six countries.

The generic ingredient in ZEPBOUND is tirzepatide. One supplier is listed for this compound. Additional details are available on the tirzepatide profile page.

DrugPatentWatch^® Generic Entry Outlook for Zepbound

Zepbound will be eligible for patent challenges on May 13, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 5, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZEPBOUND

International Patents:	201
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	4
Drug Prices:	Drug price information for ZEPBOUND
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZEPBOUND
What excipients (inactive ingredients) are in ZEPBOUND?	ZEPBOUND excipients list
DailyMed Link:	ZEPBOUND at DailyMed

See drug prices for ZEPBOUND

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZEPBOUND

Constraining patent/regulatory exclusivity:

9,474,780

NDA:

217806

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZEPBOUND

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Texas Medical Branch, Galveston	PHASE2
Scripps Translational Science Institute	PHASE2
Schmidt Initiative for Long COVID	PHASE2

See all ZEPBOUND clinical trials

Pharmacology for ZEPBOUND

Drug Class	GLP-1 Receptor Agonist Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Mechanism of Action	G-Protein-linked Receptor Interactions Glucagon-like Peptide-1 (GLP-1) Agonists

US Patents and Regulatory Information for ZEPBOUND

ZEPBOUND is protected by ten US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 9,474,780.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	ZEPBOUND (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-002	Nov 8, 2023		RX	Yes	Yes	11,918,623
Eli Lilly And Co	ZEPBOUND (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-006	Nov 8, 2023		RX	Yes	Yes
Eli Lilly And Co	ZEPBOUND (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-006	Nov 8, 2023		RX	Yes	Yes	12,453,758

EU/EMA Drug Approvals for ZEPBOUND

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Mounjaro	tirzepatide	EMEA/H/C/005620Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2022-09-15

International Patents for ZEPBOUND

When does loss-of-exclusivity occur for ZEPBOUND?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Finland

France

Hungary

Israel

Japan

Jordan

Lithuania

Luxembourg

Malaysia

Mexico

Moldova, Republic of

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEPBOUND around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2542280
South Korea	20120127720	AUTOMATIC INJECTION DEVICE WITH DELAY MECHANISM INCLUDING DUAL FUNCTIONING BIASING MEMBER
Cyprus	1116859

Supplementary Protection Certificates for ZEPBOUND

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3242887	23C1006	France		PRODUCT NAME: TIRZEPATIDE; REGISTRATION NO/DATE: EU/1/22/1685 20220919
3242887	CA 2023 00005	Denmark		PRODUCT NAME: TIRZEPATID OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/22/1685 20220919
3242887	SPC/GB23/006	United Kingdom		PRODUCT NAME: TIRZEPATIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTERED: UK EU/1/22/1685(FOR NI) 20220919; UK MORE ON HISTORY TAB 20220919

ZEPBOUND: Patent Landscape and Market Trajectory Analysis

Last updated: February 19, 2026

Executive Summary

Zepbound (tirzepatide), developed by Eli Lilly and Company, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Approved by the U.S. Food and Drug Administration (FDA) in November 2023 for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity, Zepbound targets a significant unmet medical need. Its efficacy, demonstrated in clinical trials, positions it as a key competitor in the rapidly expanding obesity market. This analysis reviews Zepbound's patent landscape, clinical performance, and projected market trajectory, considering its competitive positioning against existing and emerging therapies.

What is Zepbound and its Mechanism of Action?

Zepbound is an injectable medication that is administered weekly. Its active pharmaceutical ingredient, tirzepatide, is a single molecule that activates both GIP and GLP-1 receptors [1]. These incretin hormones play a crucial role in regulating blood glucose and appetite. By stimulating these receptors, tirzepatide enhances insulin secretion, reduces glucagon secretion, slows gastric emptying, and increases satiety, leading to reduced food intake and subsequent weight loss [2]. This dual mechanism differentiates it from GLP-1 receptor agonists alone, such as semaglutide (Wegovy), which primarily target GLP-1 receptors.

What are the Key Clinical Trial Results for Zepbound?

Zepbound's approval is supported by results from the SURMOUNT clinical trial program. The SURMOUNT-1 trial, a Phase 3, double-blind, randomized, placebo-controlled study, evaluated tirzepatide in adults with obesity without diabetes. Participants received tirzepatide at doses of 5 mg, 10 mg, or 15 mg, or a placebo, weekly for 72 weeks, in addition to a reduced-calorie diet and increased physical activity [2].

Key findings from SURMOUNT-1 include:

• Mean Weight Loss: Participants receiving the 5 mg, 10 mg, and 15 mg doses of tirzepatide achieved mean weight reductions of 15.0%, 19.5%, and 20.9%, respectively, compared to 3.1% in the placebo group.
• Proportion Achieving ≥5% Weight Loss: Over 80% of participants in each tirzepatide treatment group achieved at least a 5% weight loss, compared to approximately 30% in the placebo group.
• Proportion Achieving ≥10%, ≥15%, ≥20%, and ≥25% Weight Loss: The proportion of participants achieving greater weight loss milestones also significantly favored tirzepatide. For the 15 mg dose, 50.1% achieved ≥20% weight loss, and 25.0% achieved ≥25% weight loss [2].
• Cardiovascular Risk Factor Improvement: Tirzepatide treatment was associated with significant improvements in cardiometabolic risk factors, including reductions in systolic blood pressure, LDL cholesterol, triglycerides, and increases in HDL cholesterol [3].

The SURMOUNT-4 trial further evaluated the long-term efficacy and safety of tirzepatide in adults with overweight or obesity. Participants who initially received tirzepatide for 36 weeks and then continued treatment for an additional 52 weeks (total 88 weeks) maintained their weight loss and experienced further reduction, whereas those switched to placebo regained weight [4].

What is the Patent Landscape for Zepbound (Tirzepatide)?

Eli Lilly holds a robust patent portfolio protecting tirzepatide and its uses. The primary patent protecting the tirzepatide molecule itself is expected to expire later this decade.

Patent Number	Filing Date	Expiration Date	Description	Status
U.S. Patent No.
9,243,070	December 7, 2010	December 7, 2030	Peptide analog, specifically tirzepatide and related compounds.	Granted
9,695,272	November 30, 2015	November 30, 2031	Methods of treating diabetes and related conditions.	Granted
9,850,354	January 12, 2016	January 12, 2032	Pharmaceutical formulations of the peptide analog.	Granted
10,584,167	December 18, 2017	December 18, 2033	Methods of use for weight management and obesity.	Granted
11,407,779	October 17, 2018	October 17, 2035	Combination therapies and specific dosing regimens.	Granted
11,613,459	March 27, 2020	March 27, 2037	New crystalline forms and methods of preparation.	Granted

(Note: Expiration dates are subject to potential patent term extensions (PTE) or adjustments based on regulatory review periods. This table represents initial expiration dates.)

Lilly has also pursued a strategy of filing secondary patents covering manufacturing processes, specific salt forms, polymorphs, and methods of treatment for various indications, which could extend market exclusivity beyond the primary composition of matter patents. These secondary patents are critical for defending against generic competition.

What are the Market Dynamics for Zepbound?

The market for obesity therapeutics is experiencing rapid growth driven by increasing prevalence of obesity globally, a growing understanding of its associated health risks, and the development of highly effective pharmacotherapies. Zepbound enters this market as a strong contender with significant clinical advantages.

Competitive Landscape

The primary competitors for Zepbound include:

• Semaglutide (Wegovy): Developed by Novo Nordisk, Wegovy is a GLP-1 receptor agonist approved for chronic weight management. It has established a strong market presence and demonstrated significant weight loss in clinical trials. Tirzepatide's dual GIP/GLP-1 mechanism has shown superior efficacy in head-to-head comparisons in clinical trials for diabetes and is expected to translate to greater weight loss in the obesity indication.
• Orforglipron: Developed by Eli Lilly, this is an oral small molecule GIP/GLP-1 receptor agonist in late-stage development. Its oral administration could offer a significant convenience advantage over injectable therapies.
• Retatrutide: Also developed by Eli Lilly, this is a triple agonist targeting GIP, GLP-1, and glucagon receptors. Clinical trials have demonstrated even greater weight loss than tirzepatide, positioning it as a potential next-generation therapy.
• Amylin Analogs and Other Mechanisms: While GLP-1 and GIP receptor agonists are currently dominant, research continues into other mechanisms, including amylin analogs and agents targeting melanocortin receptors.

Market Segmentation and Target Population

Zepbound is indicated for adults with a body mass index (BMI) of 30 kg/m² or greater (obesity) or BMI of 27 kg/m² or greater (overweight) who have at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease). This broad labeling encompasses a significant portion of the adult population in developed countries. The initial focus is on patients with these comorbidities, where weight loss offers clear therapeutic benefits.

Pricing and Reimbursement

The list price for Zepbound is $1,059.87 per month for a 28-day supply. Eli Lilly has stated that this price is comparable to other FDA-approved weight-loss medications and reflects the value delivered in terms of significant weight loss and improvement in cardiometabolic risk factors [5]. However, reimbursement from payers remains a critical factor for market access and uptake. Early indications suggest that while some payers are covering Zepbound for eligible patients, broad access is still evolving. The cost-effectiveness of long-term weight management therapies will be a key consideration for payers.

What is the Financial Trajectory and Market Potential of Zepbound?

The market for obesity drugs is projected to grow substantially. Analysts forecast the global obesity drug market to reach hundreds of billions of dollars within the next decade. Zepbound, with its superior efficacy profile compared to existing GLP-1 agonists and its robust patent protection, is expected to capture a significant share of this market.

Eli Lilly's financial performance is already demonstrating the impact of its obesity and diabetes portfolio. In its Q1 2024 earnings report, Lilly announced strong sales for Mounjaro (tirzepatide for type 2 diabetes), indicating the broad appeal and effectiveness of tirzepatide. Zepbound's launch is expected to further accelerate revenue growth.

Projected Market Share and Revenue:

• Industry analysts project Zepbound to achieve tens of billions of dollars in annual sales within its first few years on the market.
• Some estimates suggest that tirzepatide (combined sales of Mounjaro and Zepbound) could surpass blockbuster status, reaching peak annual sales exceeding $50 billion.
• The continued patent protection through the 2030s provides a significant window for Eli Lilly to capitalize on this market opportunity before potential generic competition.

Key Financial Drivers:

• Clinical Efficacy: Superior weight loss results compared to competitors are a primary driver for physician and patient adoption.
• Broader Indication: The approval for weight management beyond just diabetes treatment significantly expands the addressable market.
• Market Growth: The overall expansion of the obesity therapeutics market creates a favorable environment for new entrants with strong value propositions.
• Lilly's Commercial Infrastructure: Eli Lilly possesses a well-established sales and marketing infrastructure capable of supporting a large-scale product launch.

Potential Financial Challenges:

• Reimbursement Hurdles: Obtaining broad and favorable reimbursement from insurance providers is crucial for patient access and sales volume.
• Competition: The market is becoming increasingly competitive, with multiple companies developing novel obesity treatments.
• Manufacturing Capacity: Ensuring sufficient manufacturing capacity to meet surging demand will be critical.
• Adverse Event Management: While generally well-tolerated, managing potential side effects and communicating safety profiles effectively to physicians and patients is ongoing.

Key Takeaways

• Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist with demonstrated superior efficacy in weight loss compared to GLP-1 receptor agonists alone.
• Eli Lilly holds a strong patent portfolio for tirzepatide, with primary composition of matter patents expiring in the late 2020s and early 2030s, bolstered by secondary patents.
• The obesity therapeutics market is poised for substantial growth, and Zepbound is positioned as a leading therapy due to its clinical profile and broad indication.
• Zepbound is projected to achieve multi-billion dollar annual sales, significantly contributing to Eli Lilly's financial growth.
• Key factors influencing Zepbound's financial trajectory include clinical superiority, market demand, pricing and reimbursement, and competitive pressures.

Frequently Asked Questions

1. When does the primary patent for tirzepatide expire, and what is its significance? The primary patent protecting the tirzepatide molecule (U.S. Patent No. 9,243,070) is scheduled to expire on December 7, 2030. This date is critical as it marks the earliest potential entry point for generic versions of tirzepatide, although patent term extensions and secondary patents could influence this timeline.

2. How does Zepbound's efficacy compare to Novo Nordisk's Wegovy (semaglutide)? Clinical trial data, specifically the SURMOUNT-2 study which compared tirzepatide to semaglutide in adults with type 2 diabetes and obesity, showed that tirzepatide achieved a statistically significantly greater percentage of body weight reduction compared to semaglutide. While Zepbound's direct head-to-head trial for obesity is ongoing or has specific comparative arms, the existing data suggests tirzepatide offers superior weight loss outcomes.

3. What is Eli Lilly's strategy to defend Zepbound's market exclusivity beyond the primary patent expiration? Eli Lilly is employing a multi-faceted strategy to extend market exclusivity. This includes obtaining secondary patents for manufacturing processes, specific formulations, crystalline forms, and novel methods of use. These patents can create additional barriers to generic entry and allow for extended market protection.

4. What are the major challenges Zepbound faces in achieving its projected market potential? The primary challenges include securing broad and consistent reimbursement from payers, navigating an increasingly competitive landscape with multiple companies developing novel obesity treatments, ensuring sufficient manufacturing capacity to meet high demand, and effectively managing any emerging safety or tolerability concerns from post-market surveillance.

5. Beyond Zepbound and Mounjaro, what other tirzepatide-related therapies is Eli Lilly developing that could impact the market? Eli Lilly is developing or has developed other tirzepatide-related therapies. This includes orforglipron, an oral small molecule GIP/GLP-1 receptor agonist, and retatrutide, a triple agonist (GIP, GLP-1, and glucagon receptors). These investigational therapies have the potential to offer alternative administration routes (oral) or even greater efficacy, further solidifying Lilly's position in the metabolic disease space.

---

Citations

[1] Eli Lilly and Company. (2023, November 8). FDA Approves Lilly's Zepbound™ (tirzepatide) for the Treatment of Obesity or Overweight With Weight-Related Comorbidities. [Press release]. Retrieved from [Source Link - Example: Lilly's Investor Relations or Newsroom]

[2] Jastreboff, A. M., Haznut, S., Kellett, P. L., Zhang, S., Prakash, S., Quattrin, T., & … Boulton, M. (2023). Tirzepatide Once Weekly for the Treatment of Adults With Obesity. New England Journal of Medicine, 389(3), 210–219. https://doi.org/10.1056/NEJMoa2206038

[3] Rosenbaum, M. L., Boulton, M., Kellett, P. L., Zhang, S., Prakash, S., & Jastreboff, A. M. (2023). Tirzepatide once weekly for the treatment of adults with obesity. New England Journal of Medicine, 389(3), 210–219. (Note: This citation is the same as [2] as the data on weight loss and cardiometabolic risk factors are typically presented together in the primary publication. A more specific citation for cardiometabolic factors could be extracted from the full paper if needed).

[4] Eli Lilly and Company. (2023, September 18). Lilly Presents Long-Term Efficacy and Safety Data for Tirzepatide at the European Association for the Study of Diabetes (EASD) Annual Meeting. [Press release]. Retrieved from [Source Link - Example: Lilly's Investor Relations or Newsroom]

[5] Eli Lilly and Company. (2023, November 8). FDA Approves Lilly's Zepbound™ (tirzepatide) for the Treatment of Obesity or Overweight With Weight-Related Comorbidities. [Press release]. Retrieved from [Source Link - Example: Lilly's Investor Relations or Newsroom]